



Brighter

Interim report

October - December 2020



Table of Contents.

October – December 2020.....	3
Financial overview.....	3
CEO statement.....	4
Significant events during the period.....	5
Significant events after the end of the period.	6
Comments on the financial results.....	7
Submission of interim report.....	13
Financial statements.....	14
Consolidated statement of comprehensive income.....	14
Consolidated statement of financial position.....	15
Consolidated statement of changes in equity.....	17
Consolidated statement of cash flows.....	18
Parent Company income statement.....	19
Parent Company balance sheet.....	20
Notes.....	22
About Brighter.....	29



October – December 2020.

- Net sales amounted to SEK 5,977 thousand (2,398).
- Operating result amounted to SEK -101,604 thousand (-35,029).
- Earnings before tax amounted to SEK -112,595 thousand (-34,527).
- Earnings per share, before and after dilution amounted to SEK -0.53 (-0.20).

Operating result for the period amounted to SEK -101,604 thousand (-35,029). Brighter contributed SEK -81,472 thousand to the operating result and the rest refers to Camanio and Pink Nectarine Health which were acquired in Q4 2019 and Q1 2020. Among the reasons for the higher loss were additions of to the Group of Camanio and Pink Nectarine Health and also initiated amortization of capitalized development and depreciation on equipment and installations now ready for use in production. Depreciation and amortization in total were SEK 47,697 thousand (-5,058) of which SEK 37,380 thousand refers to Brighter and the rest refers to Camanio and Pink Nectarine Health.

Average head count during the quarter (Full Time Equivalents – FTE) reached 123. The number of FTE being 84 (47) employees and 40 consultants.

Financial overview.

SEK thousands	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019	Jan-Dec 2018	Jan-Dec 2017
Net sales	5,977	2,398	12,286	2,398	0	0
Operating result	-101,604	-35,029	-226,990	-79,810	-48,605	-24,395
Net financial items	-10,991	502	-13,575	-9,875	-4,475	-2,897
Earning before tax	-112,595	-34,527	-240,565	-89,685	-53,080	-27,292
Total assets	342,880	255,664	342,880	255,664	170,616	111,354
Equity per share (SEK)	1.16	1.49	1.25	1.67	2.19	1.54
Equity ratio to total assets	75%	81%	75%	81%	63%	78%

For definitions, see note 11.



CEO statement.

The final quarter of the year was characterized by the achievement of several important commercial milestones carrying Brighter forward. We received the market approvals in Saudi Arabia and the United Arab Emirates for Actiste, initiated partnerships with two health centers in Sweden, won a nationwide framework agreement with The Swedish Association of Local Authorities and Regions (SKR) with our subsidiary Camanio, and lastly, signed two distribution agreements for Ghana and Nigeria regarding the Actiste® product portfolio. There was also a change in management, which led to me taking on the role as Acting CEO instead of the Chairmanship of the Board for the time being.

Moreover, Brighter won the Health tech Unicorn Battle Europe for its Actiste service, while our subsidiary Pink Nectarine Health won the “People’s choice award” at Techarenan Challenge 2020. Overall, it was a very eventful quarter, launching us into 2021 with a jump start. In the first week of January, we were glad to receive the market approval for the Actiste portfolio in Thailand.

Now, after taking on the role as Acting CEO on Jan 1st 2021, and looking towards the future – with the primary focus being on continued commercial progress, go-to-market activities, new partnerships and further expansion – I believe there are exciting times ahead. The recently received market approvals in several of Brighter’s key markets, the initiated Actiste user programs in Sweden, additional market approval processes underway and further expected commercial developments speaks for an eventful 2021.

At the end of January, Brighter announced a unit issue to secure additional growth capital, which will enable us to continue our commercialization efforts in key markets and strengthen our position even further. It is important not to lose momentum now, and with this capital acquisition Brighter can continue to build upon and execute on the commercial preparations made in recent years.

I look forward to being a part of the continued journey, most imminently as Acting CEO and then as we find a long-term replacement for the CEO position, I will go back to fully focus on the Board work as Chairman.

Best wishes,

Christer Trägårdh

Acting CEO of Brighter AB (publ) and board member



Significant events during the period.

Brighter's subsidiary Camanio won a nationwide framework agreement with The Swedish Association of Local Authorities and Regions (SALAR/Sveriges Kommuner och Regioner) for stationary and mobile care security alarm & response systems.

Patents for monitoring medical devices have been approved in Singapore, Mexico and Japan.

Brighter's pioneering diabetes management solutions Actiste® and Actiste® Mini, received market approval from the Saudi Food and Drug Authority (SFDA) in the Kingdom of Saudi Arabia.

On 3rd of November Camanio had record sales of almost SEK 1 million from sales of Camanio's digital therapy animals and BikeAround in Sweden and Canada.

Brighter's pioneering diabetes management solution Actiste® received market approval in the United Arab Emirates.

Brighter AB held an Extraordinary General Meeting on 20th of November. Christer Trägårdh was elected Chairman of Brighter's Board of Directors – Truls Sjöstedt stepped down from the Board.

Brighter's Nomination Committee for the Annual Shareholders' Meeting 2021 was announced, consisting of the Chairman of the Board of Brighter AB, Carl-Adam Drakenberg, Nino Armoni and Truls Sjöstedt.

Brighters CEO was notified of criminal suspicion by The Swedish Economic Crime Authority and took a voluntary time-out as CEO. Christer Trägårdh stepped in as Acting CEO and Emilie Erhardt Winiarski then remained as chairman of the board.

Brighter signed a 5-year agreement that will mean an initial order for Actiste® worth EUR 2.3 Million in Nigeria once registrations are in place.

Brighter signed a 5-year agreement that will mean an initial order for Actiste® worth EUR 1.2 Million in Ghana once registrations are in place.

Brighter carried out a directed share issue in December of c. SEK 33 million. The number of shares and votes in Brighter AB increased from 217,291,255 to 229,005,540.



Significant events after the end of the period.

Brighter's diabetes management devices Actiste® and Actiste® Mini received market approval in Thailand.

Brighter held EGM to change the limits of the share capital in the Articles of Association.

Brighter received a remaining approval for consumables related to Actiste Service in the Kingdom of Saudi Arabia.

Brighter terminated its financing arrangement with Unwrap Finance and announced the intentions to streamline operations, thus finding other investors in Camanio and Pink Nectarine Health moving forward.

The board decided to dismiss Henrik Norström as CEO and to start the search for a new CEO immediately. Christer Trägårdh remains Acting CEO until the search is concluded.

Brighter signed 5-year distribution agreement for Actiste® and Actiste® Mini in Qatar.

Brighter carried out a unit issue which was subscribed to 121% and contributed SEK 142 million to the company. Brighter's share capital will increase by SEK 5,916,137.50 and the number of shares will increase by 118,322,750 shares, to 347,328,290 shares.



Comments on the financial results.

Financial results for October-December 2020.

Income.

Net sales were 5,977 thousand (2,398). Other operating income amounted to SEK 645 thousand (538) for the period. Capitalized expenditure for development were SEK 17,351 thousand (9,729).

Operating result.

Operating result for the period amounted to SEK -101,604 thousand (-35,029). Brighter contributed SEK -81,472 thousand to the operating result and the rest refers to Camanio and Pink Nectarine Health which were acquired in Q4 2019 and Q1 2020. Among the reasons for the higher loss were the additions to the Group of Camanio and Pink Nectarine Health and also initiated amortization of capitalized development and depreciation on equipment and installations now ready for use in production. Depreciation and amortization in total were SEK -47,694 thousand (-5,068) of which SEK 40,630 thousand refers to Brighter and the rest refers to Camanio and Pink Nectarine Health.

Average headcount during the quarter (Full Time Equivalents – FTE) reached 123. The number of FTE being 84 (47) employees and 40 consultants.

The staff costs amounted to SEK -22,577 thousand (-8,941) of which SEK -9,460 thousand relates to Brighter AB and the rest refers to the operations in Camanio and Pink Nectarine Health.

Other external costs increased and amounted to SEK -42,633 thousand (-29,272), of which SEK -33,265 thousand relates to Brighter and the rest refers to the operations in Camanio and Pink Nectarine Health.

Cash flow.

At the start of the quarter, the Group had cash of SEK 14,399 thousand (32,512), decreasing to SEK 7,276 thousand (9,340) by the end of period.

Cash flow from operating activities amounted to SEK -37,623 thousand (-40,088). Investments amounted to SEK -25,614 thousand (-34,423) of which investment of SEK -18,536 thousand (-8,473) in intangible assets and SEK -7,078 (-2,461) thousand in property, plant and equipment.

Financing of SEK 56,114 thousand (51,340) after costs was raised in total during the period. Capital contributed through new issues before costs was SEK 32,800 thousand (36,531) and loans was SEK 25,000 thousand (14,895).



Total cash flow for the period amounted to SEK -7,123 thousand [-23,171].

Financial results for January-December 2020.

Income.

Net sales were SEK 12,286 thousand [2,398]. Other operating income amounted to SEK 1,787 thousand [886]. Capitalized production costs were SEK 63,632 thousand [34,563].

Operating result.

Operating result for the year amounted to SEK -226,990 thousand [-79,810]. Brighter contributed SEK -171,859 thousand to the operating result and the rest refers to Camanio and Pink Nectarine Health which were acquired in Q4 2019 and Q1 2020. Among the reasons for the higher loss were the additions to the Group of Camanio and Pink Nectarine Health and also initiated amortization of capitalized development and depreciation on equipment and installations now ready for use in production. Depreciation and amortization in total were SEK -68,374 thousand [-5,113] of which SEK 55,703 thousand refers to Brighter and the rest refers to Camanio and Pink Nectarine Health.

The staff costs amounted to SEK -74,461 thousand [-23,418] of which SEK -31,458 thousand relates to Brighter and the rest refers to the operations in Camanio and Pink Nectarine Health.

Other external costs increased and amounted to SEK -145,047 thousand [-78,409] of which SEK -107,134 thousand relates to Brighter and the rest refers to the operations in Camanio and Pink Nectarine Health.

Financial position.

Capitalized expenditure for development work during the year amounted to SEK 63,632 thousand [34,563], of which SEK 27,254 thousand relates to the development in Brighter, SEK 27,007 thousand relates to Pink Nectarine Health and SEK 9,371 thousand relates to Camanio. The acquisition of assets in Pink Nectarine Health in January 2020 added SEK 14,986 thousand in intangible assets to the Group. Book value of capitalized expenditure totaled SEK 162,309 thousand [142,630]. Patents and trademarks were SEK 7,396 thousand [6,042]. The total intangible assets are SEK 179,711 thousand [158,677] of which SEK 113,326 thousand relates to Brighter and the rest to Camanio and Pink Nectarine Health.

Book value of property, plant and equipment totaled SEK 34,957 thousand [16,470] of which equipment tools and installations in use SEK 19,971 thousand [1,332]. Also, right-



of-use assets relating to the rental agreements and leasing agreement for other assets held by the Group were SEK 14,986 thousand (2,306).

Financial assets mainly consist of shares of 13% ownership in Accumbo AB with a book value of SEK 8,995 thousand. The two companies, Accumbo and Brighter, have a partnership for development of a diabetes telehealth service to complement Accumbo's telehealth service for high blood pressure patients.

Inventory amounted to SEK 12,998 thousand (6,831) of which SEK 11,226 thousand relates to Brighter and the rest to Camanio.

Other current receivables, SEK 79,840 thousand (43,695) include pre-payments to Sanmina, for production of Actiste devices, of SEK 39,323 thousand (35,749) and short-term receivable at a nominal value of SEK 42,751 thousand. SEK 23,000 thousand of those are placed against interest. The current interest is 1% per month. The remaining receivable of SEK 19,751 thousand was written-off by SEK 15,297 thousand as it is exposed to changes in the share price of the underlying share held as security.

At the end of the year the Group had equity of SEK 255,987 thousand (207,775), an equity ratio of 75% (81%).

The Group's long-term interest-bearing debt of SEK 8,548 thousand (1,581) relates to a loan from Almi held by Camanio AB and the long-term part of leasing liabilities.

The current interest-bearing debt relates to the short-term part of Camanio's debt to Almi and short-term part of leasing liabilities. In November Brighter received a short-term loan of SEK 25,000 thousand from a private lender. The interest is 1% per month with a signing fee of 5%. Part of the loan, approx. SEK 17 million, is converted into units in the recently closed new issue.

Cash flow.

At the beginning of the year, the Group had cash of SEK 9,340 thousand (9,031) changing to SEK 7,276 thousand (9,340) by the end of the year.

Cash flow from operating activities after change in working capital amounted to SEK -177,887 thousand (-93,904). The cash flow burn rate from EBITDA within the Group is distributed approximately with 74% Brighter, 8% Camanio and 18% Pink Nectarine Health.

Investments amounted to SEK -114,343 thousand (-58,810), of which investment of SEK -66,462 thousand (-34,563) in intangible assets, and SEK -11,916 thousand (5,562) in property, plant and equipment.

Investments in financial assets of SEK 35,965 thousand consists mainly of SEK 23,000 thousand placed against interest and SEK 12,965 thousand deposited against security in shares.



Financing of SEK 290,166 thousand (153,023) after costs was raised during the year. New issues contributed SEK 276,855 thousand (149,517) of those. During 2020 new shares corresponding to SEK 31,709 thousand were subscribed by utilization of warrants TO4 and TO3 as they expired and SEK 53,800 thousand were subscribed through the financing solution with Unwrap Finance. There was a repayment of a loan to a private lender of SEK 9,000 thousand early 2020 and a new loan of SEK 25,000 thousand contributed in November.

Total cash flow for the year amounted to SEK -2,064 thousand (309).

Sales.

In Q4 Brighter signed two 5-year agreements that will mean initial orders for Actiste® and Actiste® Mini worth EUR 2.3 Million in Nigeria and EUR 1.2 Million in Ghana once registrations and market approvals are in place. In Q1 2021 the company also signed a 5-year distribution agreement with Al Danah Medical Company in Qatar. Brighter has received market approvals for Actiste in several markets: EU, Saudi Arabia, UAE and Thailand. The Actiste Mini has been approved in EU, Saudi Arabia and Thailand. In parallel, the company is working on finishing some additional internal and external go-to-market preparations and processes related to e.g. patient data management and cellular connection authorizations for its products. Moreover, there are ongoing processes in several other South East Asian markets. The company won't however speculate on when these processes will be ready. The company is also working on closing relevant strategic and commercial partnerships and contracts, sales and building a presence and network in each market.

In Europe the primary targets include Sweden and the UK. In Sweden Brighter is recruiting Actiste "Ambassadors", in promotion of the B2C online sales and continuing the development work initiated with Accumbo to launch "Diabetesdoktorn.se" (diabetes telehealth service).

Camanio is shifting from a product sales model to a recurring revenue model, a transformation that started during late 2019 but has in spite of this been able to maintain product sales during the last quarter of 2020 with an 88% increase of revenue compared to Q4 2019. The majority of the income during this quarter was therefore derived from BikeAround and digital therapy pets.

The recent award (Oct 2020) of two of five tender areas for stationary and mobile care alarms in Sweden is a clear confirmation of the potential in Camanio and the SmartCare platform.

Pink Nectarine Health AB has been developing a remote care solution for elderly care specifically targeting the home care market. This leverages our previous experience with nursing homes. In Q4, the company finalized a majority of its hardware development and has recently launched a test app together with friendly user trials.



Pink Nectarine Health was awarded the People's choice award at Techarenan in December 2020.

Future liquidity position.

The commercialization of Actiste, development and expansion of the Brighter, Camanio and Pink Nectarine Health operations requires that the Group has adequate working capital for inventory, build-up of production as well as continued product development. Funding the business is a very important part of the Group's growth strategy and a continuous part of the work of the Group Leadership. The Group has raised SEK 277 million through share issues in 2020, however, in line with the Group's expansion strategy, further financing is required. Thus in February 2021, Brighter closed a preferential unit issue raising SEK 142 million with a further potential investment of SEK 79 million from warrants exercisable in October 2021. The unit issue is expected to fund the business for 12 months. However, the Board will also strive to find alternative sources of financing for Pink Nectarine Health and Camanio from external investors and other sources of financing. Furthermore, to that the Board and Group Leadership are continuously working on and evaluating financing options for the Group to secure the funds and resources needed to pursue the necessary strategy work including financing options such as export financing, contract financing and pre-payments from customers.

Risks and uncertainty.

The principal risks and sources of uncertainty for Brighter include financial risks, such as the future earnings trend, financing, liquidity and currency and credit risks. In addition to market and commercialization risks, there are also risks associated with Brighter's operations, such as dependencies of suppliers and key personnel, obtaining necessary approval from authorities, product development, patents and intellectual property rights and product responsibility. Further information on the Group risk exposure and risk assessment work can be found in Brighter's 2019 Annual Report pages 29-33 and in Note 19.

Shareholders.

At December 31th, 2020, Brighter AB had some 12,000 shareholders, of whom the five largest represented approximately 21.1% of the capital and votes. The total number of shares amounted to 229,005,540 at the end of the year. The five largest shareholders were Försäkringsbolaget Avanza Pension (12.9%), Truls Sjöstedt (2.7%), Ålandsbanken on behalf of the owner (2.4%), Ålandsbanken AB, W8IMY (1.7%), and NA Gruppen AB (1.4%).



Warrants have been issued on several occasions. The subsidiary Brighter One AB is the holder of the warrants, to be allotted to employees, the Board, the CEO and Leadership. Brighter One has also been the holder of the currently listed TO5-series. The TO3 and TO4-series have expired. For further description and status of all the warrant programs please see Note 21 and 25 of Brighter's 2019 Annual Report.



Submission of interim report.

Stockholm, February 26th, 2021
Brighter AB (publ).

The Board of Directors and the CEO certify that the interim report for the period provides a fair view of the operations, financial position and results of the Parent Company and the Group, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.

Emilie Erhardt Winiarski	Christer Trägårdh
Chairman of the Board - interim	Acting CEO

Åsa Sjöblom Nordgren	Hab El-Assaad
Board Member	Board Member

Financial calendar.

Annual Report 2020:	2021-03-25
Interim Report Jan-Mar 2021	2021-05-12
Annual General Meeting	2021-05-17
Interim Report Apr-Jun 2021	2021-08-12
Interim Report Jul-Sep 2021	2021-11-15
Interim Report Oct-Dec 2021	2022-02-20

Review by the auditor.

This interim report has not been reviewed by the company's auditor.

Financial statements.

Consolidated statement of comprehensive income.

Amounts in SEK thousand	Note	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Net sales		5,977	2,398	12,286	2,398
Capitalized expenditure for development work		17,351	9,729	63,632	34,563
Other operating income		645	538	1,787	886
Total		23,973	12,666	77,705	37,848
Raw materials and consumables		-3,403	-1,246	-6,862	-1,246
Other external costs	3	-42,633	-29,272	-145,047	-78,409
Staff costs		-22,577	-8,941	-74,461	-23,418
Depreciation/amortization and write-offs of tangible and intangible assets		-47,694	-5,068	-68,374	-5,113
Other operating costs		-9,271	-3,168	-9,951	-7,935
Income from shares in associated companies after tax		0	0	0	-1,536
Operating result		-101,604	-35,029	-226,990	-79,810
Other financial income		3,690	762	4,048	1,548
Financial expenses		-14,681	-260	-17,623	-11,423
Net financial items		-10,991	502	-13,575	-9,875
Result before income tax		-112,595	-34,527	-240,565	-89,685
Income tax		0	0	0	0
Result for the period		-112,595	-34,527	-240,565	-89,685
Other comprehensive income:					
Translation differences on foreign operations		1,570	-48	1,646	-92
Total comprehensive income for the period		-111,025	-34,576	-238,919	-89,777
Attributable to the parent company's shareholders		-111,025	-34,576	-238,919	-89,777
Amounts in SEK		Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Earnings per share before dilution	4	-0.53	-0.20	-1.04	-0.67
Earnings per share after dilution	4	-0.53	-0.20	-1.04	-0.67



Consolidated statement of financial position.

Amounts in SEK thousand		Dec 31 2020	Dec 31 2019
Capitalized expenditure for development work		162,309	142,630
Concessions patents licenses trademarks and similar rights		7,396	6,042
Goodwill		10,007	10,005
Total intangible assets		179,711	158,677
Equipment tools and installations		19,971	1,332
Right-of-use assets		14,986	2,306
Construction in progress		0	12,831
Total property, plant and equipment		34,957	16,470
Other long-term securities		9,969	9,930
Other long-term receivables		1,647	1,663
Total financial assets		11,616	11,593
Total fixed assets		226,284	186,740
Inventories		12,998	6,831
Total inventories		12,998	6,831
Accounts receivable	5	2,524	701
Current tax assets		3,586	3,372
Other current receivables	6	79,840	43,695
Accrued income and costs		10,372	4,986
Total current receivables		96,322	52,753
Cash and cash equivalents	5,6	7,276	9,340
Total current assets		116,596	68,924
TOTAL ASSETS		342,880	255,664



Consolidated statement of financial position cont.

Amounts in SEK thousand	Note	Dec 31 2020	Dec 31 2019
Share capital		11,450	4,806
Other contributed equity		713,176	432,689
Retained earnings		-468,639	-229,720
Total Equity		255,987	207,775
Total equity attributable to the parent company's shareholders		255,987	207,775
Long-term interest-bearing debt		8,548	1,390
Other long-term liabilities		0	191
Total long-term liabilities	5,6	8,548	1,581
Accounts payable	5	27,664	13,685
Other interest-bearing debt		32,816	10,642
Deferred tax liability		3,207	0
Other current liabilities	5	4,160	6,767
Accruals and deferred income		10,499	15,215
Total current liabilities		78,346	46,308
TOTAL EQUITY AND LIABILITIES		342,880	255,664

Consolidated statement of changes in equity.

Amounts in SEK thousand	Share Capital	Other contributed equity	Result carried forward (including result for the period)	Total equity
Balance at January 1, 2019	3,722	243,138	-139,942	106,918
Result for the period			-89,685	-89,685
Translation differences on foreign operations			-92	-92
Total comprehensive income			-89,777	-89,777
Transactions with shareholders				
The value of conversion rights for convertible debt instruments	59	11,589		11,648
Value of allotted warrants		2,876		2,876
Off-setting share issue Winance	123	20,518		20,641
Conversion of convertible debt instruments	132	10,165		10,297
New issues cash and offsetting	770	144,811		145,580
Issue costs		-408		-408
Total transactions with shareholders	1,084	189,551	0	190,634
Balance at December 31 2019	4,806	432,689	-229,720	207,775
Balance at January 1, 2020	4,806	432,689	-229,720	207,775
Result for the period			-240,565	-240,565
Translation differences on foreign operations			1,646	1,646
Total comprehensive income			-238,919	-238,919
Transactions with shareholders				
New issue for cash	6,531	270,324		276,855
New issues for non-cash consideration	113	12,852		12,965
Issue costs		-2,689		-2,689
Total transactions with shareholders	6,644	280,487	0	287,131
Balance at December 31 2020	11,450	713,176	-468,639	255,987

Consolidated statement of cash flows.

Amounts in SEK thousand	Note	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Operating result		-101,604	-35,029	-226,990	-79,810
Adjustment for items not included in the cash flow	9	54,832	8,807	78,612	14,762
Interest received		0	-20	5	0
Interest paid		0	-119	-182	-7,185
Cash flow from operating activities before change in working capital		-46,772	-26,361	-148,555	-72,233
Increase/decrease in inventories		-3,910	5,890	-11,347	239
Increase/decrease in operating receivables		-6,808	-15,637	-17,061	-14,876
Increase/decrease in operating liabilities		19,866	-3,980	-924	-7,034
Total change in working capital		9,149	-13,727	-29,332	-21,671
Cash flow from operating activities		-37,623	-40,088	-177,887	-93,904
Investments in intangible assets		-18,536	-8,473	-66,462	-34,563
Investments in property, plant and equipment		-7,078	-2,461	-11,916	-5,562
Investments and loans to associated companies		0	-12,859	0	-8,055
Investment in financial assets		0	-10,629	-35,965	-10,629
Cash flow from investing activities		-25,614	-34,423	-114,343	-58,810
Loans raised/paid		25,000	14,895	16,000	4,000
New share issues and warrants		32,800	36,531	276,855	149,517
New share issue costs		-1,685	-86	-2,689	-494
Cash flow from financing activities		56,114	51,340	290,166	153,023
Cash flow for the period		-7,123	-23,171	-2,064	309
Opening cash and cash equivalents		14,399	32,512	9,340	9,031
Closing cash and cash equivalents		7,276	9,340	7,276	9,340



Parent Company income statement.

Amounts in SEK thousand	Note	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Sales		1	0	10	0
Capitalized expenditure for development work		6,526	9,729	27,254	34,563
Other operating income		348	368	735	368
Total		6,875	9,897	27,999	34,931
Other external costs		-32,964	-25,358	-104,614	-71,093
Staff costs		-8,296	-5,444	-27,281	-17,443
Depreciation/amortization of tangible and intangible as- sets		-41,069	-4,355	-56,373	-4,400
Other operating costs		-3,800	-3,145	-2,833	-7,904
Total operating costs		-86,129	-38,303	-191,101	-100,841
Operating result		-79,253	-28,406	-163,102	-65,909
Other interest income and similar income		8	196	3,561	982
Interest expenses and similar expenses		-37,867	-139	-53,576	-18,519
Total result from financial items		-37,859	56	-50,015	-17,537
Result after financial items		-117,112	-28,349	-213,117	-83,446
Appropriations		0	0	0	0
Tax on result for the period		0	0	0	0
Result for the period		-117,112	-28,349	-213,117	-83,446



Parent Company balance sheet.

Amounts in SEK thousand	Note	Dec 31 2020	Dec 31 2019
Capitalized expenditure for development work		105,989	128,576
Concessions, patents, licenses, trademarks and similar rights		7,337	5,966
Total intangible assets		113,326	134,542
Equipment, tools and installations		18,712	131
Construction in progress		0,000	12,831
Total property, plant and equipment		18,712	12,963
Shares in Group companies		64,440	17,789
Other long-term securities		9,960	9,960
Other long-term receivables		1,647	1,634
Total financial assets		76,047	29,382
Total fixed assets		208,084	176,887
Inventories		12,858	4,808
Total inventories		12,858	4,808
Receivables on group companies		38,020	19,286
Other receivables		83,201	46,407
Accrued income and costs		7,290	4,460
Total current receivables		128,512	70,153
Cash at bank and in hand		597	7,006
Total current assets		141,967	81,967
TOTAL ASSETS		350,051	258,854



Parent Company balance sheet cont.

Amounts in SEK thousand	Note	Dec 31 2020	Dec 31 2019
Share capital		11,450	4,806
Development expenses fund		105,989	109,979
Restricted equity		117,439	114,784
Share premium		713,176	432,121
Result carried forward		-320,573	-241,522
Result for the period		-213,117	-83,446
Unrestricted equity		179,487	107,152
Total equity		296,926	221,936
Accounts payable			11,760
Convertible loans		19,388	0
Other interest-bearing debt		26,250	9,000
Other liabilities		1,020	1,109
Accruals and deferred income		6,467	15,048
Total current liabilities		53,125	36,918
TOTAL EQUITY AND LIABILITIES		350,051	258,854

Notes.

Note 1 Accounting policies.

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report.

Significant accounting and valuation principles are detailed on in Note 1 in Brighter's 2019 Annual Report. Important estimates and assumptions for accounting purposes can be found in Brighter's 2019 Annual Report in Note 3.

Note 2 General information.

Brighter AB (publ.) corporate registration number 556736-8591 is a Parent Company registered in Sweden, with its registered office in Stockholm, at Borgarfjordsgatan 18, SE-164 40 Kista, Sweden. The business is located at this address. Brighter develops technical and digital medical devices with a primary area of application in the treatment of diabetes. Brighter AB (publ) has a wholly owned subsidiary, Brighter One AB, the only function of which is to hold warrants as part of the external financing of the Group and as part of the incentive programs. Brighter AB also has a subsidiary in United Arab Emirates. The name of this government-contract-eligible mainland subsidiary is Brighter Software Trading L.L.C., with management control held by Brighter AB.

From the fourth quarter 2019, Brighter AB has a wholly owned subsidiary in Camanio AB as well as the two subsidiaries wholly owned by Camanio AB; Camanio Care Inc. and Bestic AB.

From January 2020, Brighter AB acquired Pink Nectarine Health AB, which became a wholly owned subsidiary.

Brighter AB is listed on Nasdaq First North Growth Market (BRIG). The Brighter Certified Adviser on Nasdaq First North Growth Market is Eminova Fondkommission AB. Phone: +46 (8) 684 211 00. E-mail: info@eminova.se.

The figures in the report are reported in SEK thousand unless otherwise stated.

Note 3 Specification of other external costs

Other external costs for the year of SEK 145,047 thousand (78,409) mainly consist of consultancy costs.

Brighter's other external costs are SEK 107,134 thousand of which SEK 55,647 thousand relates to FTE consultants and another SEK 28,873 thousand are other consultant costs. An FTE consultant contributes in every way equal to an employee, but receives payment over invoice.

Pink Nectarine Health's other external costs are SEK 22,880 thousand of which SEK 11,726 refers to FTE consultants.

Camanio's other external costs are is SEK 15,275 thousand of which SEK 9,371 thousand refers to FTE consultants.

Note 4 Earnings per share.

SEK thousand	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Result for the period attributable 100% to the parent company's shareholders	-117,112	-28,349	-213,117	-83,446
Number of shares at end of period before dilution*	229,005,540	142,138,507	229,005,540	142,138,507
Number of shares at end of period after dilution	252,181,621	146,150,559	252,181,621	146,150,559
Weighted average number of shares before dilution	221,196,017	139,462,966	204,312,350	124,634,961
Earnings per share (SEK) as a weighted average before dilution	-0.53	-0.20	-1.04	-0.67
Earnings per share (SEK) as a weighted average after dilution	-0.53	-0.20	-1.04	-0.67

* Average number of shares has been recalculated according to IAS 33 for the periods preceding the completed rights issue in 2020.

Note 5 Financial instruments.

Financial Assets.

SEK thousand	Dec 31 2020	Dec 31 2019
Financial assets valued at fair value over P & L	9,969	9,930
Assets at acquisition value		
Accounts receivable	2,524	701
Depositions on collaboration and rental agreements	1,647	1,663
Short-term interest-bearing receivable*	27,454	0
Cash and cash equivalents	7,276	9,340
Total	48,870	21,634

Financial Liabilities.

SEK thousand	Dec 31 2020	Dec 31 2019
Long-term interest-bearing debt	8,548	1,581
Short-term interest-bearing debt	32,816	10,642
Accounts payable	27,664	13,685
Total	69,027	25,908

*Short-term interest-bearing receivable consists of a short-term placement of SEK 23 million against interest and a receivable of SEK 19,751 thousand, together at a nominal value of SEK 42,751 thousand. The receivable of SEK 19,751 was written-off by SEK 15.3 million as the value of that receivable depends on the share price of the underlying security in shares.

Note 6 Borrowing and net liabilities.

SEK thousand	Dec 31 2020	Dec 31 2019
Long-term		
Long-term interest-bearing debt	8,548	1,581
Short-term		
Liabilities relating to interest-bearing debt or convertible bonds	32,816	10,642
Total borrowing	41,363	12,223
Short-term interest-bearing receivable	27,454	0
Cash and cash equivalents	7,276	9,340
Net debt interest-bearing liabilities	6,633	2,883
Equity	255,987	207,775
Debt to equity ratio	2.6%	1.4%

Note 7 Transactions with affiliated parties.

Transactions with affiliated parties in the form of remuneration, in addition to the Board fee, were carried out with the following Board members. From January 1st to September 30th Jan Stålemark received a fee of SEK 481,650 for consultancy services on implementation of OKRs and SEK 600,000 as acting CEO for Pink Nectarine Health. Tove Andersson received SEK 171,654 for consultancy work regarding blockchain. Emanuel Lipschütz received SEK 44,100 for consultancy services. Christer Trägårdh received SEK 80,000 for consultancy services. The amounts are exclusive of VAT. All transactions are carried out on a commercial basis. Truls Sjöstedt is fully employed by Brighter and has received salary according to his employment agreement.



Note 8 Segment information.

Brighter's operating segments consists of Brighter, Camanio and Pink Nectarine Health.

Brighter AB develops mobile solutions in health-tech that facilitates treatment, collects reliable data and enables communication between the patient, relatives and healthcare. Initially, the offer is focused on diabetes.

Camanio AB develops digital solutions for care primarily aimed at the elderly in their home or at retirement homes. The company offers digital service platforms in healthcare, robotics, digital tools and smart technology.

Pink Nectarine Health AB is a Swedish company that develops artificial intelligence solutions within elderly care at home or in nursing homes. The initial offer was, in the form of a bracelet, focused on detecting falls and creating a safe and yet independent life for the elderly person.

Net sales

There has been a smaller transaction between the segments invoiced at cost of purchases. The revenues from external customers that are reported for the segments to the Group leadership are valued in the same way as in the consolidated income statement.

Segments assets and liabilities

The segment's assets and liabilities are measured in the same way as in the financial reports. Assets and liabilities are allocated based on the segment's operations.

Net Sales from customers per segment.

SEK thousand	Jan-Dec 2020	Jan-Dec 2019
Segments		
Brighter	10	0
Camanio	10,865	2,438
Pink Nectarine Health	1,655	0
Elimination	-243	-40
Total Group Net Sales from customers	12,286	2,398



Earnings before tax per segment.

SEK thousand	Jan-Dec 2020	Jan-Dec 2019
Segments		
Brighter	-203,057	-85,288
Camanio	-23,645	-4,397
Pink Nectarine Health	-31,563	0
Elimination	17,700	0
Total Group Earnings before tax Group	-240,565	-89,685

Assets per segment.

SEK thousand	Dec 31 2020	Dec 31 2019
Segments		
Brighter	360,001	248,719
Camanio	39,628	32,707
Pink Nectarine Health	44,966	0
Elimination	-101,716	-25,763
Total Assets Group	342,880	255,663

Liabilities per segment.

SEK thousand	Dec 31 2020	Dec 31 2019
Segments		
Brighter	63,417	36,965
Camanio	10,980	19,642
Pink Nectarine Health	50,516	0
Elimination	-38,020	-8,718
Total Liabilities Group	86,893	47,889

Note 9 Acquisitions.

Pink Nectarine Health AB.

On January 31st Brighter AB acquired 100% of Pink Nectarine Health AB shares. Pink Nectarine Health AB had before the acquisition acquired all the assets in Noomi AB. The acquisition was made through a set-off of shares in Brighter AB at a value of SEK 12,965 thousand. The number of shares issued were 2,266,682 shares at the share price of 5.72 SEK/share, as established through the average VWAP of the 20 days before the day of execution, on the 31st of January. There were no transaction costs. At the beginning 2021 a claw-back clause in the acquisition SPA repaid SEK 2,452 thousand in cash to Brighter bringing the final acquisition price down to SEK 10,513 thousand. Below is the final purchase price analysis.

Intangible assets	14,986
Property plant and equipment	506
Inventories	4,797
Short-term receivables	313
Deferred tax liability	-3,207
Short-term liabilities	-6,883
Total	10,513
Acquisition price	10,513
Remaining value/ Goodwill	0

Note 10 Specification of items not included in the cash flow.

SEK thousand	Oct-Dec 2020	Oct-Dec 2019	Jan-Dec 2020	Jan-Dec 2019
Depreciation/amortization and write-offs of tangible and intangible assets	47,694	5,068	68,374	5,113
Income from shares in associated companies after tax	0,000	0,000	0,000	1,536
Write-off inventories	7,133	2,912	9,977	7,286
Capital gain/loss on assets	0,000	0,095	0,017	0,641
Currency gain/loss	0,005	0,074	0,244	0,186
Specification of items not included in the cash flow	54,832	8,149	78,612	14,762



Note 11. Financial key figures.

Definition of key figures

Net sales	Sales to external customers
Operating profit/loss	Profit/loss before financial items
Profit/loss for the period	Profit/loss after financial items
Earnings per share	Shareholders' equity via the number of outstanding shares before dilution
Operating margin %	Total income via operating profit/loss
Equity ratio %	Shareholders' equity via balance sheet total
Debt to equity ratio	Interest-bearing liabilities in relation to shareholders' equity
Net debt	Interest-bearing liabilities less interest-bearing assets and cash and cash equivalents
Working capital	All current assets minus current liabilities
Net financial items	Financial income minus financial costs
Balance sheet total	Total assets on balance sheet
Other external costs	All costs included in operating profit/loss, except for costs of goods sold, personnel costs and depreciation and share of earnings from associated companies.

About Brighter.

Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, Brighter's aim is to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Besides the wholly owned and controlled subsidiaries Camanio and Pink Nectarine Health, Brighter has made a strategic investment in digital care provider Accumbo.




Proactive and data driven medical care.

Brighter has developed unique solutions and services based on patented technology that aim to facilitate more proactive, efficient and data driven medical care, primarily with regard to diabetes under the “Actiste” brand family. The solutions are based on a concept that Brighter refers to as “The Benefit Loop” – a personal, holistic and data centered approach to medical care. The Company has also made a strategic investment in Swedish digital care provider Accumbo, which focuses on hypertension [high blood pressure]. Accumbo has successfully launched the Blodtrycksdoktor [Blood Pressure Doctor] service in Sweden and is now working in parallel on development of a similar service for diabetes [“Diabetesdoktor” [Diabetes Doctor]], which is based on Brighter's technology.

Digital care and support in the home.

During 2019 and 2020, Brighter expanded into the “age-tech” and care sector through the acquisitions of Camanio and Pink Nectarine Health, focusing on innovative technology and services for care and support in the home. Subsidiary Camanio has a broad product portfolio comprising both digital services and physical products enabling a smooth transition to digital care at home. Brighter's other subsidiary, Pink Nectarine Health, has developed a remote monitoring solution using AI technology to give seniors the confidence to live independently at home for longer, without having to compromise their privacy or dignity, feeling safe and secure knowing that if they experience a health issue, help is always near.





For further information, please contact:

Christer Trägårdh, Acting CEO

Phone: +46 70 456 30 02

E-mail: christer.tragardh@brighter.se

Ann Zetterberg, CFO

Phone: +46 708 37 21 23

E-mail: ann.zetterberg@brighter.se

This information is such information, as Brighter AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact persons for publication on February 26, 2021 at 16:15 CET.

